comparative effectiveness research, personalized medicine, and health reform harold c. sox, m.d.,...
TRANSCRIPT
![Page 1: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/1.jpg)
Comparative Effectiveness Research, Personalized
Medicine, and Health Reform
Harold C. Sox, M.D., MACP
Co-chair, the IOM committee for Initial Priority Setting for CER
Editor EmeritusAnnals of Internal Medicine
![Page 2: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/2.jpg)
Personalized Medicine
• The United States Congress defines personalized medicine as "the application of genomic and molecular data to better target the delivery of health care, facilitate the discovery and clinical testing of new products, and help determine a person's predisposition to a particular disease or condition."
![Page 3: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/3.jpg)
Personalized Medicine:
The Health Policy Context
![Page 4: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/4.jpg)
“Seriously, we basically have to solve the health cost problem, or nothing else matters.”
Paul Krugman
NY Times blog on restoring a healthy US economy, September 28, 2009
![Page 5: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/5.jpg)
Cutting Costs: the Senate Finance Bill• Reduce market-basket updates of Medicare
payments to providers.• Reduce subsidies to pre-paid Medicare• Link Medicare payments to quality of care• Reduce Part D subsidies for the wealthy• Independent commission to advise Congress on
Medicare rates.• Reduce Medicare DSH payments.• Initiate Accountable Care Organizations (like a
medical home)
![Page 6: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/6.jpg)
Cutting Costs: Senate Finance
• Create an Innovation Center in CMS– Test strategies for patient-centered care,
reduced costs, and better quality.
• Reduce payment for preventable hospitalizations.
• Increase Part D drug cost rebates
http://www.kff.org/healthreform/sidebyside.cfm
![Page 7: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/7.jpg)
Will current legislation control costs?
• A member of the group, Elizabeth A. McGlynn, associate director of RAND Health, said that her firm’s research showed that the legislation would do more to provide benefits for the uninsured than to change the overall upward trajectory in spending.
• “We are not really seeing a lot of evidence that the trajectory would change very much,” Ms. McGlynn said.
![Page 8: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/8.jpg)
Personalized Medicine
• The United States Congress defines personalized medicine as "the application of genomic and molecular data to better target the delivery of health care, facilitate the discovery and clinical testing of new products, and help determine a person's predisposition to a particular disease or condition."
![Page 9: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/9.jpg)
Comparative Effectiveness Research (CER):
What is it?
Why all the interest?
![Page 10: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/10.jpg)
What drives the costs of health care?
• The availability of expensive technology
• Technological innovation
• High prices
• Uncertainty about effectiveness
• Profit-taking
• Imperfect markets
• Patients need; doctors decide; someone else pays.
![Page 11: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/11.jpg)
What drives the costs of health care?
• The availability of expensive technology
• Technological innovation
• High prices
• Uncertainty about effectiveness
• Profit-taking
• Imperfect markets
• Patients need; doctors decide; someone else pays.
![Page 12: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/12.jpg)
$ 3,922$ 4,439$ 4,940$ 5,444$ 6,304
Per-capitaMedicare Spending1996 2000
Per-capita spending across Per-capita spending across intensity quintiles intensity quintiles
Ratio: High to Low: 1.61 1.58
$ 5,229$ 5.692$ 6,069$ 6,614$ 8,283
![Page 13: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/13.jpg)
What expenditures drive small area variations?
Wennberg. Health Affairs. February 13, 2002Wennberg. Health Affairs. February 13, 2002
![Page 14: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/14.jpg)
A rationale for better evidence
• When the evidence is good, service rates don’t vary across low and high utilization regions.– That should be reassuring.
• When evidence is lacking, rates are higher in regions with high utilization.
• Perhaps—just perhaps—better evidence will reduce unwanted variation in health care practices.
![Page 15: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/15.jpg)
CER in the American Recovery and Reinvestment Act of 2009
• $1.1B for CER research– $400M to NIH– $300M to AHRQ– $400M to the Secretary, DHHS
• Mandated IOM study to establish initial priorities for conditions to study with CER funding.– Due date: June 30, 2009
![Page 16: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/16.jpg)
The IOM Committee’s working definition of CER
The generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, or to improve the delivery of care.
The purpose of CER is to assist consumers, clinicians, purchasers, and policy makers to make informed decisions that will improve health care at both the individual and population levels.
Source: iom.edu/cerprioritiesSource: iom.edu/cerpriorities
![Page 17: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/17.jpg)
What’s unique about CER?It includes all of the following
• Direct, head-to-head comparisons.• Broad range of topics.
– tests, treatments, strategies for prevention, care delivery and monitoring
• A broad range of beneficiaries: – patients, clinicians, purchasers, and policy
makers.
• Study populations representative of clinical practice
• Focus on patient-centered decision-making– tailor the test or treatment to the specific
characteristics of the patient.
![Page 18: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/18.jpg)
“Patient-centered”
• Suppose a RCT shows that A>B, but many patients got better on B.– Lacking any additional knowledge, you should
prefer A.
• Is it possible that some patients would have done better on B than A?– Can we identify them in advance?
• Demographic predictors• Clinical predictors
![Page 19: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/19.jpg)
The Promise of CER
Information to help doctors and patients make better decisions
![Page 20: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/20.jpg)
2,606 recommended CER topics received from 1758 respondents to web-based questionnaire
IOM Committee’s Voting Process
Round1 Voting = 1,268 nominated topics 200 topics
Round 2 Voting = 145 rank-ordered topics
Committee discusses each topicRound 3 Voting on 155 nominated topics
Round 3 Results = Final 100 priority topics
![Page 21: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/21.jpg)
Figure 5.1 Distribution of the recommended research priorities by primary and secondary research areas
![Page 22: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/22.jpg)
The IOM: the CER program should also:
• Do priority-setting on an ongoing basis.• Have a broadly representative oversight
committee• Engage public participation at all levels of CER• Support large-scale, clinical and administrative
data networks• Do research on dissemination of CER findings• Support research and innovation in the methods
of CER• Expand and support the CER workforce
![Page 23: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/23.jpg)
CER: Senate Finance
• Support comparative effectiveness research by establishing a public-private Center for Comparative Effectiveness Research to conduct, support, and synthesize research on outcomes, effectiveness, and appropriateness of health care services and procedures. – An independent CER Commission will oversee the
activities of the Center. – [E&C Committee amendment: Prohibit use of
comparative effectiveness research findings to deny or ration care or to make coverage decisions in Medicare.]
http://www.kff.org/healthreform/sidebyside.cfm
![Page 24: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/24.jpg)
CER is coming. Everyone has an interest in seeing it succeed
What can you do to help?
![Page 25: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/25.jpg)
Helping CER to succeed
• Learn what CER can do (and what it can’t or won’t do).
• Speak up. Share your knowledge with others.
![Page 26: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/26.jpg)
How could CER improve decision making about
personalized medicine?
![Page 27: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/27.jpg)
Measuring the value of genetic tests
• Genetic markers are tests
• What’s the best way to measure the value of tests?– Diagnostic: predicting current disease status – Prognostic: predicting future outcomes
![Page 28: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/28.jpg)
What do tests do?• Disease detection
– Diagnostic tests– “What is the present state of this patient?”– “What is the probability that this patient has this
disease?”– How to measure: do a cross-sectional study
• Disease prediction– Prognostic tests– “What is the probability that this patient will develop
this disease in the future?”– How to measure: Do a cohort study.
![Page 29: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/29.jpg)
Tests aren’t perfect• They miss disease, and they give false
alarms. • Therefore, we have to interpret them in terms
of probability, not certainty.• The question to ask:
– Diagnostic tests: “how much will the test change the probability that the patient has a disease?”
– Prognostic tests: “how much will the test change the probability that the patient will develop a disease?”
![Page 30: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/30.jpg)
Evaluating diagnostic tests
• Measures of test performance – Sensitivity and specificity
• Sensitivity:
– % of diseased patients with + test
• Specificity:– % of non-diseased patients with - test
![Page 31: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/31.jpg)
Types of test results
Disease present
Disease absent
Test pos
True-positive
False-positive
Test neg
False-negative
True-negative
ND+ ND-
![Page 32: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/32.jpg)
Types of test results
Disease present
Disease absent
Test pos
TP FP
Test neg
FN TN
ND+ ND-
Sensitivity= TP/ND+
Specificity = TN/ND-
![Page 33: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/33.jpg)
Evaluating diagnostic tests
• Sensitivity and specificity do not necessarily imply health effects– Need to measure consequences of test
results
• PET scanning in cancer: a political challenge for Medicare a method for using test performance
measures to estimate health effects
![Page 34: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/34.jpg)
Evaluate studies of test performance
Test sensitivity and specificity
Calculate post-test probability
Does test result change probability enough to change
management?
![Page 35: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/35.jpg)
Evaluate studies of test performance
Test sensitivity and specificity
Calculate post-test probability
Does test result change probability enough to change
management?
YesNoDon’t dotest
Do test
![Page 36: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/36.jpg)
How much does the probability of disease change after a test
result?
• Bayes Theorem:
Post-test odds = pre-test odds x LR
• LR+= sens / (1-spec)
• LR- = (1-sens) / spec
![Page 37: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/37.jpg)
Example: PET scanning to detect scar recurrence of colon cancer
• Is an firm area near the original incision – scar tissue?– a local recurrence of cancer?
• The choice:– Do a biopsy now– Do a PET scan and biopsy if it’s positive.
![Page 38: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/38.jpg)
The effect of PET on management
• Does a negative PET scan lower the probability of recurrence enough to alter the decision to biopsy the mass?– Pre-test probability of recurrence = 0.69– Sensitivity of PET = 0.96– Specificity of PET = 0.98
• Use Bayes’ theorem to calculate post-test probability of recurrence
Post-test odds = pre-test odds x Likelihood Ratio
![Page 39: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/39.jpg)
Post-test probability of recurrent CRC after PET scan of peri-operative scar
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
pre-test probability of recurrence
post-te
st p
robab
ility
of re
curr
ence
p[CRC if PET+]
p[CRC if PET-]
![Page 40: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/40.jpg)
Prognostic tests
• What is the probability that this person will develop diabetes in 10 years?– Age, BP, blood sugar, body weight, TG level,
family history of diabetes, body mass index.
• How much will the probability change if the patient has genetic polymorphisms that predict future diabetes?
![Page 41: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/41.jpg)
Joint Effects of Common Genetic Variants on the Risk for Type 2
Diabetes in U.S. Men and Women of European Ancestry
Cornelis et al. Ann Intern Med. 2009; 150: 541 - 550.
![Page 42: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/42.jpg)
• Genome-wide association studies have identified genetic polymorphisms associated with diabetes mellitus (DM).– Individual variants are weakly associated
• Study questions:– With more polymorphisms, does the risk of
DM increase?– How much does genetic information improve
the prediction of DM compared with clinical information alone?
![Page 43: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/43.jpg)
• Use 2 large cohorts (NHS [1976] and HPFS [1980]) followed through 2002.– Blood collected 23 and 13 years after start.
• Case control design:– Cases: 1297 men and 1612 women who developed DM– Controls: 1338 men and 2163 women without diabetes.
• Tested for 17 SNPs from 13 genetic loci.– Calculated genetic risk score (GRS)
• Tested association of SNP score with development of DM, adjusting for:– Body mass index, exercise, family history of diabetes,
diet
![Page 44: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/44.jpg)
Analysis• Tested whether SNP score predicts the
development of DM, adjusting for:– Predictors of DM: BMI, exercise, FHx, diet
• Calculated area under ROC curve (a measure of discrimination)– Clinical factors only– Clinical factors + GRS
• Area under ROC = probability that someone who gets DM has a higher GRS than someone who does not get DM.
![Page 45: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/45.jpg)
Cornelis, M. C. et. al. Ann Intern Med 2009;150:541-550
Association of reported loci and risk for type 2 diabetes in pooled analysis of men and women
![Page 46: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/46.jpg)
Cornelis, M. C. et. al. Ann Intern Med 2009;150:541-550
Genetic risk score and risk for type 2 diabetes
![Page 47: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/47.jpg)
Cornelis, M. C. et. al. Ann Intern Med 2009;150:541-550
Receiver-operating characteristic curves for type 2 diabetes
![Page 48: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/48.jpg)
Study conclusions• The GRS significantly improved case–control
discrimination beyond that afforded by conventional risk factors, but the magnitude of this improvement was marginal: – Addition of the GRS increased the AUC by only 1%.
• Caveat: given the design of our study, we could not precisely estimate the predictive power of the GRS and were limited to discriminatory analysis.
• Comment: they did not do a net reclassification analysis.– Would show directly how many subjects change risk
category due to genetic information.
![Page 49: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/49.jpg)
Conclusions
• The goal of CER: help doctors and patients make better decisions.
• CER can help measure the extra value of a test– Diagnostic tests: difference in probability of
disease.– Prognostic tests: difference in discrimination
or the probability of getting a disease.
• Better evidence about tests could reduce the cost of health care.
![Page 50: Comparative Effectiveness Research, Personalized Medicine, and Health Reform Harold C. Sox, M.D., MACP Co-chair, the IOM committee for Initial Priority](https://reader035.vdocuments.us/reader035/viewer/2022070305/5514f11b55034693478b5ea7/html5/thumbnails/50.jpg)
Questions for the future
• Will Congress enact a national CER program?• Will a CER Program promote research to
improve decision making?• Will doctors and patients use the results of
CER?• Will better evidence narrow differences in
utilization rates in high and low geographic areas lower health care costs.
• For which diseases will genetic testing improve prediction of disease susceptibility?